Recent Publications

  1. Outcome of Elective Switching to Vedolizumab in Inflammatory Bowel Disease Patients Under Tumor Necrosis Factor Antagonist-Maintained Clinical Remission.

    Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakyraba A.

    J Gastroenterol Hepatol. 2019. [Epub ahead of print June 6 2019].

    PMID: 331169926.

  2. Follow-up of Ulcerative Colitis Patients Who Have Achieved Histological Normalization.
    Israel A, Christensen B, El Jurdi K, Rai V, Ollech JE, Cohen RD, Sakuraba A, Dalal SR, Rubin DT.

    Clin Gastroenterol Hepatol. 2019. [Epub ahead of print June 19 2019]

    PMID: 31228567.

  3. Ustekinumab is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis.

    Ollech JE, Rubin DT, Glick L, Weisshof R, El Jurdi K, Israel A, Krugliak Cleveland N, Hyman N, Sakuraba A, Pekow J, Cohen RD, Dalal SR.

    Dig Dis Sci. 2019. [Epub ahead of print June 9 2019]

    PMID: 31187322

  4. Challenges in IBD Research: Pragmatic Clinical Research.

    Scott FI, Rubin DT, Kugathasan S, Bousvaros A, Elson CO, Newberry RD, Melmed GY, Pekow J, Fleshman JW, Boyle BM, Mahadevan U, Cannon LM, Long MD, Cross RK, Ha CY, Lasch KL, Robinson AM, Rafferty JF, Lee JJ, Dahl KDC, Weaver A, Shtraizent N, Honig G, Hurtado-Lorenzo A, Heller CA.

    Inflamm Bowel Dis. 2019;25(Supplement_2):S40-S47.

    PMID: 31187322

  5. Patient and Physician Preferences for Ulcerative Colitis Treatments in the United States.

    Boeri M, Myers K, Ervin C, Marren A, DiBonaventura M, Cappelleri JC, Hauber B, Rubin DT.

    Clin Exp Gastroenterol. 2019;12:263-278. [In Press].

  6. Proposal to Update the Curriculum in Inflammatory Bowel Diseases for Categorical Gastroenterology Fellows.

    Malter LB, Israel A, Rubin DT.

    Inflamm Bowel Dis. 2019. [Epub ahead of print May 22 2019].

    PMID: 31115448.

  7. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s and Colitis Foundation.

    Park KT, Ehrlich OG, Allen JI, Meadows P, Szigethy EM, Henrichsen K, Kim SC, Lawton RC, Murphy SM, Regueiro M, Rubin DT, Engel-Nitz NM, Heller CA.

    Inflammatory Bowel Dis. 2019 [Epub ahead of print May 21 2019].

    PMID: 31112238.

  8. Targeted Mutational Analysis of Inflammatory Bowel Disease-Associated Colorectal Cancers.

    Alpert L, Yassan L, Poon R, Kadri S, Niu N, Patil SA, Mujacic I, Montes D, Galbo F, Wurst MN, Zhen CJ, Cohen RD, Rubin DT, Pekow JR, Weber CR, Xiao SY, Hart J, Segal J, Setia N.

    Human Pathology. 2019. [Epub ahead of print May 2 2019].

    PMID: 31054900.

  9. The Renin-Angiotensin System Promotes Colonic Inflammation by Inducing TH17 Activation via the JAK2/STAT Pathway.

    He L, Du J, Chen Y, Liu C, Zhou M, Adhikari S, Rubin DT, Pekow J, Li YC.

    Am J Physiol Gastrointest Liver Physiol. 2019;316:G774-G784.

    PMID: 30995068.

  10. De-Escalating Medical Therapy in Crohn’s Disease Patients Who Are in Deep Remission: A RAND Appropriateness Panel.

    Sparrow MP, Melmed GY, Devlin S, Kozuch P, Raffals L, Loftus EV Jr, Rubin DT, Speigel B, Baidoo L, Bressler B, Cheifetz A, Irving P, Jones J, Kaplan GG, Velayos F, Siegel CA.

    GastroHep. 2019;1(3):108-117. [In Press]

  11. Patient Support Program Increased Medication Adherence with Lower Total Healthcare Costs Despite Increased Drug Spending.

    Brixner D, Rubin DT, Mease P, Mittal M, Liu H, David M, Ganguli A, Fendrick AM.

    J. Manag. Care Spec. Pharm. 2019;25(7):770-779].

    PMID: 31081461

  12. Histologic Remission in Ulcerative Colitis - Are We There Yet?

    Long MD and Rubin DT.

    Am J Gastroenterol. 2019;114(5):713-715.

    PMID: 31021831.

  13. ACG Clinical Guideline: Ulcerative Colitis in Adults.

    Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD.

    Am J Gastroenterol. 2019;114(3):384-413.

    PMID: 30840605.

  14. Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn’s Disease After Ileal Resection.

    Glick L, Sossenheimer PH, Cohen RD, Hyman NH, Hurst RD, Rubin DT.

    J Crohns Colitis. 2019. [Epub ahead of print February 27 2019].

    PMID: 30809655.

  15. Capsule Retention in Crohn’s Disease: A Meta-Analysis.

    Pasha SF, Pennazio M, Rondonotti E, Wolf D, Buras MR, Albert JG, Cohen SA, Cotter J, D’Haens G, Eliakim R, Rubin DT, Leighton JA.

    Inflamm Bowel Dis. 2019. [Epub ahead of print May 3 2019].

    PMID: 31050736.

  16. Differential Risk of Disease Progression Between Isolated Anastomotic Ulcers and Mild Ileal Recurrence After Ileocolonic Resection in Patients with Crohn’s Disease.

    Ollech JE and Aharoni-Golan M, Weisshof R, Normatov I, Sapp AR, Kalakonda A, Israel A, Glick L, Karrison T, Dalal SR, Sakuraba A, Cohen RD, Rubin DT, Pekow J.

    Gastrointest Endosc. 2019. [Epub ahead of print February 6 2019].

    PMID: 30738034.

  17. Real-World Experience of Tofacitinib in IBD at Tertiary Center.

    Weisshof R and Aharoni-Golan M, Sossenheimer PH, El Jurdi K, Ollech JE, Pekow J, Cohen RD, Sakuraba A, Dalal S, Rubin DT.

    Dig Dis Sci. 2019;64(7):1945-1951.

    PMID: 30734234.

  18. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe.

    Weisshof R and Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT.

    J Crohns Colitis. 2019. [Epub ahead of print February 6 2019].

    PMID: 30726894.

  19. Faecal Calprotectin is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-Escalation in Patients with Inflammatory Bowel Disease.

    Buisson A, Mak WY, Andersen MJ Jr, Lei D, Kahn SA, Pekow J, Cohen RD, Zmeter N, Pereira B, Rubin DT.

    J Crohns Colitis. 2019. [Epub ahead of print February 6 2019].

    PMID: 30726887.

  20. IBD-Associated Colon Cancers Differ in DNA Methylation and Gene Expression Profiles Compared to Sporadic Colon Cancers.

    Pekow J, Hernandez K, Meckel K, Deng Z, Haider HI, Khalil A, Zhang C, Talisila N, Siva A, Jasmine F, Li YC, Rubin DT, Hyman N, Bissonnette M, Weber C, Kibriya MG.

    J Crohns Colitis. 2019. [Epub ahead of print February 11 2019].

    PMID: 30753380.

  21. Patient-Provider Communications About Pharmacogenomic Results Increase Patient Recall of Medication Changes.

    Borden BA, Lee SM, Danahey K, Galecki P, Patrick-Miller L, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreuer K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, Stadler WM, Kavitt RT, Meltzer DO, Ratain MJ, O'Donnell PH.

    Pharmacogenomics J. 2019. [Epub ahead of print February 11 2019].

    PMID: 30713337.

  22. Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients.

    Sossenheimer PH, Glick LR, Dachman A, Skowron KB, Rubin M, Umanskiy K, Smith R, Cannon L, Hurst RD, Cohen RD, Hyman NH, Rubin DT.

    Dis Colon Rectum. 2019;62(4):463-469.

    PMID: 30540661.

  23. Discussion of Code Status in the Per-Endoscopic Period.

    Rao VL, Feld LD, Rubin DT.

    Am J Gastroenterol. 2019;114(3):372-374.

    PMID: 30333550.

  24. Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease.

    Raffals LE, Nguyen GC, Rubin DT.

    Clin Gastroenterol Hepatol. 2018. [Epub ahead of print September 7 2018].

    PMID: 30196164.

  25. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-Term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials.

    Feagan BG, Sandborn WJ, Colombel JF, O’Byrne S, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT.

    J Crohns Colitis. 2019:13(1):50-57.

    PMID: 30203005.

More articles by Dr. Rubin are available on

Note:  Underlined authors were Dr. Rubin’s trainees or students at the time of authorship